IMFINZI 50 mg/mL concentrate for solution for infusion

DRUG6 trials

Conditions

Biliary Tract CancerDLL3 Expressing Tumors Including Small Cell Lung CancerNon-Small cell lung cancer (NSCLC)Stage III Non Small Cell Lung Cancerbladder carcinomamalignant melanomanon small cell lung cancer (NSCLC)renal cell carcinoma

Phase 1

A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants with Solid Tumours (IMFINZI-subQ)

Not yet recruitingCTIS2025-521639-34-00

AstraZeneca AB• Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

Target: 4Updated: 2026-03-27

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

Not yet recruitingCTIS2025-523438-24-00

Ideaya Biosciences Inc.DLL3 Expressing Tumors Including Small Cell Lung Cancer

Target: 35Updated: 2026-07-03

Phase 2

Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02

RecruitingCTIS2025-521251-24-00

Fundacion GECPNon-Small cell lung cancer (NSCLC)

Start: 2025-12-01Target: 68Updated: 2025-09-08

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

Not yet recruitingCTIS2025-522801-39-00

Intergroupe Francophone De Cancerologie ThoraciqueStage III Non Small Cell Lung Cancer

Target: 177Updated: 2026-07-02

Phase 3

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Not yet recruitingCTIS2025-523085-24-00

AstraZeneca ABBiliary Tract Cancer

Target: 27Updated: 2026-03-23

Phase 4

BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology

RecruitingCTIS2025-523620-44-02

Semmelweis Universitybladder carcinoma, malignant melanoma, non small cell lung cancer (NSCLC) +3